^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

Excerpt:
…we report that LKB1/KRAS mutant NSCLC cell lines are sensitive to the MEK inhibitor CI-1040 shown by a dose-dependent reduction in proliferation rate…
DOI:
10.1038/sj.bjc.6604886